Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
A study published by David Cheng, Postdoctoral Scientist, Neuroscience Research, University of New South Wales, NSW, Australia, says that CBD has a potential as a preventive measure against symptoms of Alzheimer’s. This presents yet another exciting development for medical researchers, given the persistent challenges to finding effective solutions for this condition.
A number of difficulties exist in evaluating published data on CBD or marijuana use for epilepsy. The extremely limited published studies were small, poorly described, and not well designed. Contributing to the difficulty of interpreting published studies, CBD products are not produced under the guidance of good manufacturing practices (GMP) and are not subject to regulations governing labeling, purity, and reliability. In other words, currently, there is no guarantee of consistency between products, or even differing lots produced by the same manufacturer. Without independent testing (e.g. USP certification) of CBD products for content and purity, as well as bioavailability testing of specific products, uncertainty surrounds the use of available CBD products in routine clinical settings.
In fact, not only will CBD not make you high, it has been proven to counteract the psychoactivity of THC. This property makes CBD highly useful as a medical treatment for a wide range of conditions. In terms of the CBD products you can buy, the amount of THC present varies from none at all in a pure CBD Isolate to a minimal amount (less than 0.3%) in a Full-Spectrum CBD product.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
While it is still classed illegal on a Federal level, individual U.S. states have adopted a more lenient policy towards this plant and some states now allow it for recreational use. The easing up of state laws has also allowed researchers to explore this miraculous plant and only recently has it been found to be an effective treatment for a variety of medical problems due to its CBD oil benefits. From cancer, anorexia, pain and inflammation management it seems like medical marijuana is placing a strong footing within the medical industry.
Dr. Cohen has found that chronic conditions including autoimmune diseases and pain syndromes can be helped with a 6-mg under-the-tongue tincture (the fastest delivery system) or a 25-mg capsule taken twice a day. Dosages for topical products like lotions are especially hard to determine—there’s no clarity on how much CBD gets into the system through the skin.
John Staughton is a traveling writer, editor, and publisher who earned his English and Integrative Biology degrees from the University of Illinois in Champaign, Urbana (USA). He is the co-founder of a literary journal, Sheriff Nottingham, and calls the most beautiful places in the world his office. On a perpetual journey towards the idea of home, he uses words to educate, inspire, uplift and evolve.
This is the second time Moon Mother Hemp Company has placed among the top five brands on our ranking. The Colorado-based company, which was founded about a year ago, sets the bar very high for quality (including USDA-certified organic hemp) without charging the moon for its products. Their tinctures taste so good, you may be sad you don’t need more.